Safusidenib (AB-218, DS-1001)
Safusidenib 250 mg BID
250 mg · Single arm
IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)
36-month PFS rate: 79.1%, median follow-up 38.8 months
J201 Phase 2 · NCT04458272
Disease Pipeline Tools IDH-mutant glioma
IDH-mutant glioma
Programs, trials, and reported response and survival for IDH-mutant glioma.
IDH-mutant glioma
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
6 arms have a reported figure in this set.
Safusidenib 250 mg BID
250 mg · Single arm
IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25)
36-month PFS rate: 79.1%, median follow-up 38.8 months
J201 Phase 2 · NCT04458272
Ivosidenib, non-enhancing glioma
Phase 1 doses · Single arm
recurrent non-enhancing IDH1-mutant glioma
median PFS: 13.6 months, 95% CI 9.2 to 33.2
Ivosidenib Phase 1 (glioma) · NCT02073994
Vorasidenib 40 mg daily
40 mg · ITT
grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)
Comparator: placebo
median PFS, vorasidenib: 27.7 months, NEJM 2023
median PFS, placebo: 11.1 months, NEJM 2023
median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminary
INDIGO · NCT04164901
Vorasidenib, non-enhancing glioma
Phase 1 doses · Single arm
recurrent non-enhancing IDH-mutant glioma (n = 22)
median PFS: 36.8 months, Phase 1
IDH1-vac
not stated in source · Single arm
newly diagnosed IDH1 R132H astrocytoma
3-year PFS rate: 63%
NOA-16 · NCT02454634
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.